Summary
A 38-year-old federal contractor was denied a security clearance under Guideline H (Drug Involvement) due to illegal marijuana use and purchases. Between February 2015 and March 2017, while already holding a security clearance, the applicant engaged in the illegal use and purchase of marijuana. This activity raised specific disqualifying conditions under Adjudicative Guidelines paragraphs 25(a), 25(c), and 25(f).
Although the applicant ceased marijuana use in March 2017, the judge determined that this cessation, coupled with the passage of time, was insufficient to mitigate the security concerns. The decision highlighted that the applicant's past drug involvement raised significant questions about reliability and trustworthiness.
Ultimately, the applicant failed to demonstrate the necessary level of reliability and trustworthiness, partly due to continued association with friends who used marijuana. Consequently, the security clearance was denied.
Why the Applicant Was Denied
- The applicant illegally used and purchased marijuana while holding a security clearance.
- The applicant's past drug involvement raised significant security concerns that were not mitigated by the passage of time.
- The applicant failed to demonstrate reliability and trustworthiness, and continued to associate with marijuana-using friends.
Conditions Referenced
- AG ¶ 25(a)raisedSubstance Misuse
- AG ¶ 25(c)raisedIllegal Possession of a Controlled Substance
- AG ¶ 25(f)raisedIllegal Drug Use While Granted Access to Classified Information
Key Rule Quoted
“Any doubt concerning personnel being considered for access to classified information will be resolved in favor of the national security.”
Procedural Posture
- SOR issuedNov 22, 2019
- Answer filedDec 28, 2019
- Hearing heldAug 7, 2020rescheduled due to COVID-19 restrictions
- Decision dateOct 16, 2020
Cite For
- Denial Based on Illegal Drug Use While Holding a Security Clearance
- Insufficient Evidence of Reliability and Trustworthiness After Substance Misuse
- Security Concerns Under Guideline H Regarding Drug Involvement